Glycoprotein Acetyl Detection for Atrial Fibrillation Risk Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical tools primarily focus on predicting the risk of coronary artery disease and stroke, neglecting the need for accurate identification of individuals at risk for other circulatory diseases such as chronic rheumatic heart disease, pulmonary heart disease, and atrial fibrillation, which could benefit from targeted screening and preventative treatment.
Innovation Solution
A method involving the determination of quantitative values of specific biomarkers like glycoprotein acetyls, fatty acid ratios, and metabolic indicators in biological samples, compared to control values, to assess the risk of developing atrial fibrillation and/or flutter, using nuclear magnetic resonance spectroscopy or other analytical methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current clinical tools focus on predicting risk of coronary artery disease and stroke, then prediction accuracy for these specific diseases is improved, but the ability to predict risk for other circulatory diseases (atrial fibrillation, pulmonary heart disease, etc.) deteriorates
Solution Approach 1:
The patent applies universality by developing a comprehensive biomarker panel that can predict risk for multiple types of circulatory diseases (coronary artery disease, stroke, atrial fibrillation, pulmonary heart disease, chronic rheumatic heart disease, and other heart diseases) using the same testing framework. This multi-functional approach allows a single test system to serve various clinical prediction needs rather than requiring separate specialized tests for each disease type.
Solution Approach 2:
The patent utilizes parameter changes by measuring multiple different biomarkers (including but not limited to troponin, creatinine, glucose, cholesterol, and other circulating substances) and analyzing their quantitative values to predict risk across different circulatory disease types. By changing and expanding the set of measured parameters, the system achieves both high prediction accuracy for specific diseases and broad applicability across multiple disease categories.
2Measurement precision
If multiple different biomarkers are measured to improve prediction accuracy for various circulatory diseases, then prediction accuracy is improved, but the complexity of the testing procedure increases
Solution Approach 1:
The patent applies merging by combining multiple different biomarker measurements into a single integrated testing procedure and report system. Rather than requiring separate tests for each biomarker and disease type, the system merges the measurement and analysis of multiple substances (troponin, creatinine, glucose, cholesterol, and other circulating substances) into one comprehensive test that delivers prediction results for various circulatory diseases simultaneously, thereby reducing overall procedural complexity.
Solution Approach 2:
The patent utilizes segmentation by dividing the complex biomarker panel into specific groups of substances that can be measured together using standardized methodologies. The testing procedure is segmented into manageable components (different biomarker categories) that can be analyzed systematically, allowing for improved prediction accuracy while maintaining procedural organization and reducing complexity through structured analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the prediction of circulatory diseases, particularly atrial fibrillation and flutter, by improving screening and preventative treatment efficacy, even when combined with established risk factors, and potentially replacing the need for other tests.
Implementation Method 1
glycoprotein acetyls refers to a nuclear magnetic resonance spectroscopy signal that represents the abundance of circulating glycated proteins
Data Source
Figure 1a
Figure 1b
Figure 2a
AI summary
A method for determining whether a subject is at risk of developing certain circulatory diseases is disclosed.